Nabriva Therapeutics to Present Data at IDWeek 2021
Nabriva Therapeutics (NASDAQ: NBRV) announced the presentation of data at the IDWeek 2021, scheduled from September 29 to October 3, 2021. The company and its collaborators will focus on the efficacy of lefamulin against Staphylococcus aureus in children with cystic fibrosis. This data will be part of a poster presentation titled “In Vitro Activity of Lefamulin against Staphylococcus aureus isolated from the Lower Respiratory Tract of Children with Cystic Fibrosis.” Nabriva is known for its anti-infective agents, particularly the first pleuromutilin antibiotic, XENLETA, for community-acquired bacterial pneumonia.
- None.
- None.
DUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced data presentation at the Infectious Disease Society of America (IDSA) IDWeek™ 2021, taking place virtually from September 29 – October 3, 2021.
Nabriva, along with its collaborators, will exhibit a poster presentation on the in vitro activity of lefamulin against Staphylococcus aureus isolated from the lower respiratory tract of children with cystic fibrosis. XENLETA® (lefamulin) is a first-in-class pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia (CABP).
PRESENTATION:
Session Title: Respiratory Infections - Bacterial
Poster Title: “In Vitro Activity of Lefamulin against Staphylococcus aureus isolated from the Lower Respiratory Tract of Children with Cystic Fibrosis”
Session ID: 1058520
Presenting Author: Dr. Helio S. Sader, M.D., Ph.D., FIDSA (Sr. Director, JMI Laboratories)
About Nabriva Therapeutics plc
Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA® (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). Nabriva Therapeutics is also developing CONTEPO™ (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis. Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO® (tedizolid phosphate) in the United States and certain of its territories.
Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for Nabriva Therapeutics, including but not limited to statements about the ability of Nabriva Therapeutics to raise awareness of XENLETA and SIVEXTRO, drive prescription demand growth and drive top-line sales growth, the potential benefits to patients of SIVEXTRO and XENLETA, the market opportunity for SIVEXTRO and XENLETA, the availability of SIVEXTRO through major U.S. specialty wholesalers, the impact on Nabriva Therapeutics’ reported revenue from anticipated sales of SIVEXTRO, the sufficiency of its cash resources and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: Nabriva Therapeutics’ ability to comply with its obligations under its loan agreement with Hercules, Nabriva Therapeutics’ ability to maintain the conditions under the distribution agreement to exclusively distribute and promote SIVEXTRO, including its ability to maintain a commercial infrastructure sufficient to promote and distribute SIVEXTRO, the extent of business interruptions resulting from the infection causing the COVID-19 outbreak or similar public health crises, the ability to retain and hire key personnel, the availability of adequate additional financing on acceptable terms or at all and such other important factors as are set forth in Nabriva Therapeutics’ annual and quarterly reports and other filings on file with the SEC. In addition, the forward-looking statements included in this press release represent Nabriva Therapeutics’ views as of the date of this press release. Nabriva Therapeutics anticipates that subsequent events and developments may cause its views to change. However, while Nabriva Therapeutics may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Nabriva Therapeutics’ views as of any date subsequent to the date of this press release.
CONTACTS:
For Investors
Kim Anderson
Nabriva Therapeutics plc
ir@nabriva.com
For Media
Andrea Greif
Ogilvy
andrea.greif@ogilvy.com
914-772-3027
FAQ
What will Nabriva Therapeutics present at IDWeek 2021 related to NBRV?
When is IDWeek 2021 taking place for Nabriva Therapeutics?
What is the focus of Nabriva's poster presentation at IDWeek 2021?
What is XENLETA and its significance for Nabriva Therapeutics?
Who is presenting the data for Nabriva at IDWeek 2021?
